Atara Biotherapeutics Inc... (ATRA)
Atara Biotherapeutics Statistics
Share Statistics
Atara Biotherapeutics has 5.86M shares outstanding. The number of shares has increased by -95.54% in one year.
| Shares Outstanding | 5.86M |
| Shares Change (YoY) | -95.54% |
| Shares Change (QoQ) | 1.51% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 3.8M |
| Failed to Deliver (FTD) Shares | 11.38K |
| FTD / Avg. Volume | 5.52% |
Short Selling Information
The latest short interest is 636.28K, so 11.05% of the outstanding shares have been sold short.
| Short Interest | 636.28K |
| Short % of Shares Out | 11.05% |
| Short % of Float | 14.75% |
| Short Ratio (days to cover) | 7.11 |
Valuation Ratios
The PE ratio is -1.17 and the forward PE ratio is -1.07. Atara Biotherapeutics's PEG ratio is 0.01.
| PE Ratio | -1.17 |
| Forward PE | -1.07 |
| PS Ratio | 0.77 |
| Forward PS | 0.2 |
| PB Ratio | -1.02 |
| P/FCF Ratio | -1.45 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Atara Biotherapeutics Inc. has an Enterprise Value (EV) of 86.2M.
| EV / Earnings | -1.01 |
| EV / Sales | 0.67 |
| EV / EBITDA | -1.14 |
| EV / EBIT | -1.03 |
| EV / FCF | -1.25 |
Financial Position
The company has a current ratio of 0.48, with a Debt / Equity ratio of -0.31.
| Current Ratio | 0.48 |
| Quick Ratio | 0.4 |
| Debt / Equity | -0.31 |
| Total Debt / Capitalization | -44.4 |
| Cash Flow / Debt | -2.3 |
| Interest Coverage | -18.08 |
Financial Efficiency
Return on equity (ROE) is 0.88% and return on capital (ROIC) is 123.83%.
| Return on Equity (ROE) | 0.88% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | 123.83% |
| Revenue Per Employee | $842,745.1 |
| Profits Per Employee | $-558,189.54 |
| Employee Count | 153 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 1.97 |
Taxes
| Income Tax | -12K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -60.23% in the last 52 weeks. The beta is 0.49, so Atara Biotherapeutics's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | -60.23% |
| 50-Day Moving Average | 7.71 |
| 200-Day Moving Average | 9.39 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 206.32K |
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.4M in profits. Earnings per share was -11.41.
| Revenue | 128.94M |
| Gross Profit | 107.93M |
| Operating Income | -83.44M |
| Net Income | -85.4M |
| EBITDA | -75.75M |
| EBIT | -83.44M |
| Earnings Per Share (EPS) | -11.41 |
Balance Sheet
The company has 25.03M in cash and 29.91M in debt, giving a net cash position of -4.88M.
| Cash & Cash Equivalents | 25.03M |
| Total Debt | 29.91M |
| Net Cash | -4.88M |
| Retained Earnings | -2.05B |
| Total Assets | 109.1M |
| Working Capital | -69.68M |
Cash Flow
In the last 12 months, operating cash flow was -68.72M and capital expenditures -246K, giving a free cash flow of -68.96M.
| Operating Cash Flow | -68.72M |
| Capital Expenditures | -246K |
| Free Cash Flow | -68.96M |
| FCF Per Share | -9.21 |
Margins
Gross margin is 83.71%, with operating and profit margins of -64.71% and -66.23%.
| Gross Margin | 83.71% |
| Operating Margin | -64.71% |
| Pretax Margin | -66.24% |
| Profit Margin | -66.23% |
| EBITDA Margin | -58.75% |
| EBIT Margin | -64.71% |
| FCF Margin | -53.48% |
Dividends & Yields
ATRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -165.36% |
| FCF Yield | -170.59% |
Analyst Forecast
The average price target for ATRA is $17.5, which is 153.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $17.5 |
| Price Target Difference | 153.6% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jun 20, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Jun 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -28.28 |
| Piotroski F-Score | 3 |